Online inquiry

IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6066MR)

This product GTTS-WQ6066MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CCL2 gene. The antibody can be applied in Pulmonary Fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002982.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6347
UniProt ID P13500
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6066MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14381MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8707MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ3117MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ1323MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ7693MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ1688MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ12964MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ3990MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW